Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

26.92USD
19 Jan 2018
Change (% chg)

$-0.86 (-3.10%)
Prev Close
$27.78
Open
$27.82
Day's High
$28.09
Day's Low
$26.85
Volume
3,534,841
Avg. Vol
1,546,892
52-wk High
$41.20
52-wk Low
$25.06

Latest Key Developments (Source: Significant Developments)

Acadia Pharmaceuticals posts Q3 loss of $0.53 per share
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.53.Q3 sales $35.6 million versus I/B/E/S view $32 million.Sees FY 2017 sales $124 million to $127 million.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

ACADIA Pharmaceuticals Q2 loss per share $0.55
Tuesday, 8 Aug 2017 04:38pm EDT 

Aug 8 (Reuters) - ACADIA Pharmaceuticals Inc :Q2 sales $30.5 million.Q2 loss per share $0.55.ACADIA Pharmaceuticals Inc - ‍expects that full-year NUPLAZID net sales for 2017 will be between $105 million and $115 million​.ACADIA Pharmaceuticals - ‍at June 30, 2017, co's cash, cash equivalents, investment securities totaled $417.3 million, versus $529.0 million at December 31, 2016​.  Full Article

Acadia pharmaceuticals Q2 loss per share $0.55
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Acadia Pharmaceuticals Inc :Acadia pharmaceuticals reports second quarter 2017 financial results.Q2 sales $30.5 million.Q2 loss per share $0.55.Sees fy 2017 sales $105 million to $115 million.Q2 revenue view $20 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.  Full Article

Acadia Pharmaceuticals reports Q1 revenue $15.3 million
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals reports first quarter 2017 financial results.Q1 revenue $15.3 million versus I/B/E/S view $15.2 million.Q1 loss per share $0.72.Q1 earnings per share view $-0.73 -- Thomson Reuters I/B/E/S.Acadia Pharmaceuticals Inc says plan to advance Alzheimer's disease psychosis (ad psychosis) program into phase III in second half of 2017.  Full Article

Acadia Pharmaceuticals Q4 loss per share $0.65
Tuesday, 28 Feb 2017 04:05pm EST 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016 . Q4 loss per share $0.65 .Q4 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.  Full Article

Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer's disease psychosis
Tuesday, 20 Dec 2016 07:00am EST 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer's disease psychosis . Pimavanserin met primary endpoint showing a statistically significant reduction in psychosis versus placebo .Pimavanserin was generally well tolerated.  Full Article

Acadia Pharmaceuticals initiates phase II trial of Pimavanserin
Tuesday, 15 Nov 2016 09:00am EST 

Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia.  Full Article

Acadia Pharmaceuticals announces proposed public offering of common stock
Monday, 8 Aug 2016 04:01pm EDT 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals announces proposed public offering of common stock .Acadia Pharmaceuticals Inc says that it intends to offer and sell, subject to market and other conditions, $200 million of its common stock.  Full Article

Acadia Pharmaceuticals reports Q2 2016 financial results
Thursday, 4 Aug 2016 04:05pm EDT 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals reports second quarter 2016 financial results .Qtrly loss per share $0.63.  Full Article

UK's CMA could accept undertakings on Acadia's Priory Group deal
Thursday, 28 Jul 2016 07:09am EDT 

UK's CMA : To look at Acadia's undertakings offer in relation to acquisition of Priory Group No 1 Ltd in detail . Considers that undertaking offered, or a modified version of it, might be accepted .Now has until 23 September to decide whether to accept undertaking, with possibility to extend this timeframe to 18 november.  Full Article